AbbVie lags J&J in cMet

AbbVie today claimed a mid-stage win with its cMet-targeting ADC telisotuzumab vedotin in second-line non-small cell lung cancer. However, response rates have slipped since a previous update, and have also fallen short of those seen with Johnson & Johnson’s Rybrevant plus lazertinib in a somewhat similar population. With Teliso-V AbbVie is taking aim at cMet overexpressers, for whom there are currently no approved treatments, estimating that around a quarter of advanced EGFR wild-type NSCLC patients overexpress cMet. In the uncontrolled phase 2 Luminosity trial toplined today overall response rates were 35% and 23% in cMet high and intermediate patients respectively. At an earlier update AbbVie reported corresponding ORRs of 54% and 25%. And, at this year’s ASCO, J&J saw a 61% response rate in cMet overexpressers treated with Rybrevant plus lazertinib in the Chrysalis-2 trial. Like Luminosity, Chrysalis-2 enrolled second-line NSCLC patients, but unlike Luminosity, it focused on EGFR mutants. AbbVie has previously flagged the potential for accelerated approval of Teliso-V; a phase 3 trial in second-line cMet-overexpressing NSCLC is ongoing, with a docetaxel comparator arm. Several companies are also developing cMet-targeted ADCs, and AbbVie itself has another bite at the cherry with ABBV-400. 

cMet-targeting ADCs in clinical development

Source: OncologyPipeline.